Boosting oxygen diffusion in the radioresistant Oesophageal tumour microenvironment to improve radiation response

Maitiú Ó Murchú

Maitiú Ó Murchú has also been awarded the Breakthrough Cancer Research PhD Scholarship 2021. He joined the team of Prof Jacintha O’Sullivan as a PhD student in Trinity College Dublin and work in collaboration with Dr. Helena Kelly’s team in the Royal College of Surgeons, Ireland.

Maitiú’s research focuses on Oesophageal Cancer. Oesophageal cancer is a cancer of the food pipe, and only 20% of people diagnosed with this cancer are alive after 5 years.  Patients with oesophageal cancer can be treated with radiation prior to surgery. Radiation treatment is given to reduce tumour size prior to surgery. Unfortunately, up to 70% of these patients do not respond, and their tumour can actually increase in size by the time of surgery due to their non-response to radiation treatment.

Maitiú’s PhD research project aims to test if this non-response to radiation is due to a reduced level of oxygen in the tumour, and to see if this can be fixed by increasing oxygen levels using the new hydrogel, Oxygel, an oxygen-carrying gel which can be injected directly into the tumour. This project will use oesophageal cancer cells which are resistant to radiation and tumour samples consented by oesophageal cancer patients to determine whether Oxygel improves response to radiation. These experiments will allow us to preliminarily test the action of Oxygel on these cells and patient samples, providing information regarding the following: How does Oxygel affect the metabolism and survival of these cancer cells? How long should we treat the cells with Oxygel to see these effects? What doses of Oxygel are most optimal? Does Oxygel boost response to radiation in patient samples? Can Oxygel be used with other treatment approaches?

With an approximate 20% 5-year survival rate, oesophageal cancer is a dismal cancer with unmet clinical needs. New treatment options are urgently required for the approximate 450 annual oesophageal cancer patients in Ireland, and their families and friends. This Breakthrough Cancer Research PhD Scholarship will contribute towards a pre-clinical data package which aims to position Oxygel as a new treatment approach for oesophageal cancer patients, particularly for those who do not respond to radiation treatment.

 

RESEARCH FINDINGS

Publications

Ó Murchú M, Lin X, Tutty MA, Cahill C, Miller I, Jensen L, Prina-Mello A, Lynam-Lennon N, Maher SG, Kelly H, O’Sullivan J. Enhancing cancer radiotherapy efficacy using NanOx, a novel oxygenating perfluorocarbon nanoemulsion that reverses tumour hypoxia. Cancer Lett. 2024 Dec 22;611:217406. doi: 10.1016/j.canlet.2024.217406. Epub ahead of print. PMID: 39716484.

 

Conferences Presentations

CRYSTAL3 Annual Meeting 2022, Valladolid, Spain. Title: “Boosting O2 Diffusion to Improve Radiation Response in Oesophageal Adenocarcinoma”.

Irish Radiation Research Society Meeting 2023. Dublin, Ireland. Title: “Boosting Oxygen Diffusion in the Radioresistant Oesophageal Adenocarcinoma Tumour Microenvironment”.

IARC Conference 2023. Athlone, Ireland. Title: “Development of an Oxygen-Carrying Perfluorocarbon Nanoemulsion to Boost Oxygen Diffusion and Improve Response to Radiotherapy in Oesophageal Adenocarcinoma”.

Association for Radiation Research (ARR) Conference 2024, Birmingham, UK. Title: “Oxygen-Carrying Perfluorocarbon Nanoemulsion Radiosensitises an Isogenic Model of Oesophageal Adenocarcinoma Radiation Resistance”.

Irish Radiation Research Society Meeting 2024. Belfast, Northen Ireland. Title: “Boosting Oxygen Diffusion in the Radioresistant Oesophageal Adenocarcinoma Microenvironment to Enhance Radiotherapy”.

EACR-AACR-IACR EAI Conference 2024. Dublin, Ireland. Title: “Oxygen-Carrying Perfluorocarbon Nanoemulsions Radiosensitise an Isogenic Model of Oesophageal Adenocarcinoma Radiation Resistance”.

IARC Conference 2024. Dublin, Ireland. Title: “Developing O2-Carrying Perfluorocarbon Nanoemulsions to Improve Radiotherapy in Oesophageal Adenocarcinoma”

 

Awards

Travel Award -to attend CRYSTAL3 Annual Meeting 2022

Breakthrough’s Social Media Content Creator Award – 2023

Best Postgraduate Oral Presentation Award – TTMI Conference 2023

Best Poster Award – Association for Radiation Research (ARR) 2024 Conference, Birmingham, UK.

Travel Award – to attend Association for Radiation Research (ARR) 2024

Best Abstract – Irish Radiation Research Conference 2024

 

 

Back
Start year
2021
End year
2024
Principal Investigator
Prof. Jacintha O’Sullivan & Dr. Helena Kelly
Researcher
Maitiú Ó Murchú
Institution
Trinity College Dublin
Grant Funding
Breakthrough Cancer Research PhD Scholarship
Linked Breakthrough Research Priorities
research-priorities-icon1

Increase research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.

research-priorities-icon3

Fund the discovery and development of new therapeutics, surgical approaches and technologies, including biological and immune approaches, to improve cancer treatment.

research-priorities-icon4

Fund research which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.